234 related articles for article (PubMed ID: 16206114)
1. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
3. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
[TBL] [Abstract][Full Text] [Related]
5. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
Friedland G; Khoo S; Jack C; Lalloo U
J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
[TBL] [Abstract][Full Text] [Related]
10. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A
BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India.
Ramachandran G; Bhavani PK; Hemanth Kumar AK; Srinivasan R; Raja K; Sudha V; Venkatesh S; Chandrasekaran C; Swaminathan S
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1564-8. PubMed ID: 24200269
[TBL] [Abstract][Full Text] [Related]
12. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
[TBL] [Abstract][Full Text] [Related]
13. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.
Burman W; Benator D; Vernon A; Khan A; Jones B; Silva C; Lahart C; Weis S; King B; Mangura B; Weiner M; El-Sadr W;
Am J Respir Crit Care Med; 2006 Feb; 173(3):350-6. PubMed ID: 16109981
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
[TBL] [Abstract][Full Text] [Related]
16. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis.
Narita M; Stambaugh JJ; Hollender ES; Jones D; Pitchenik AE; Ashkin D
Clin Infect Dis; 2000 May; 30(5):779-83. PubMed ID: 10816148
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
Holland DP; Hamilton CD; Weintrob AC; Engemann JJ; Fortenberry ER; Peloquin CA; Stout JE
Pharmacotherapy; 2009 May; 29(5):503-10. PubMed ID: 19397460
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.
Manosuthi W; Sungkanuparph S; Thakkinstian A; Vibhagool A; Kiertiburanakul S; Rattanasiri S; Prasithsirikul W; Sankote J; Mahanontharit A; Ruxrungtham K
AIDS; 2005 Sep; 19(14):1481-6. PubMed ID: 16135901
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.
Matteelli A; Villani P; Carvalho AC; El-Hamad I; Cusato M; Apostoli A; Marcantoni C; Calabresi A; Dal Zoppo S; Bigoni S; Regazzi M
J Antimicrob Chemother; 2012 Oct; 67(10):2470-3. PubMed ID: 22678727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
